FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 648 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation MOST POPULAR Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... November 3, 2025 ESMO Congress 2022, 9-13 September August 22, 2022 Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... May 3, 2023 FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 Load more HOT NEWS News digest – Genetic links to male breast cancer, bowel cancer... FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... K9 Police Officer In Berlin Beats Breast Cancer For Second Time
